MedTrace Logo

The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients

NCT02648659 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-08-09

No results posted yet for this study

Summary

This study assessed the effect of tailored eradication therapy according to Clarithromycin resistance in Helicobacter pylori patients.

Conditions

  • Peptic Ulcer

Interventions

DRUG

Ilaprazole

Ilaprazole 10mg 1tablet qid(4 times/day)

DRUG

Amoxicillin

Amoxicillin 500mg 1capsule qid(4times/day)

DRUG

Clarithromycin

Clarithromycin 500mg 1tablet bid(2times/day)

DRUG

Metronidazole

Metronidazole 250mg 2tablets tid(3times/day)

Sponsors & Collaborators

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Seong Woo Jeon · Kyungpook national university medical center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-02
Primary Completion
2017-01-06
Completion
2017-02-14

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648659 on ClinicalTrials.gov